Irina Stanoevich

Irina Stanoevich


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2019 in Problems of Endocrinology
Verified
Journal Article
Open access
AGAnna Gorbacheva
Anna Gorbacheva
EPElena Przhiyalkovskaya
Elena Przhiyalkovskaya
VAVilen N. Azizyan
Vilen N. Azizyan
ISIrina Stanoevich
Irina Stanoevich
AGAndrey Yu. Grigoriev
Andrey Yu. Grigoriev
ZBZhanna Belaya
Zhanna Belaya
From 14 to 54% of all pituitary adenomas are nonfunctioning pituitary adenomas (NPAs), their prevalence is estimated as 7.041.3 cases per 100 000 population. The most common type of NPAs (73% of cases) are gonadotropinomas. In most cases, gonadotropinoma is characterized by secretion of biologically inactive hormones, so the release of gonadotropins does not lead to the development of any clinical symptoms. For this reason the diagnosis of gonadotropinomas is most often performed on the basis of immunohistochemical analysis. However, in rare cases, gonadotropinomas secrete biologically active hormones, most often follicle-stimulating (FSH). Ovarian hyperstimulation syndrome due to gonadotropin-secreting pituitary tumors occurs in about 3% of women with hormonally inactive pituitary adenomas at reproductive age and in 8% of patients with verified gonadotropinomas. This clinical case describes a young patient with a rare pathology: FSH/LH-secreting macroadenoma of the pituitary, which led to the development of ovary hyperstymulation symdrome. The diagnosis of pituitary adenoma was performed due to the identified hyperprolactinemia one month before the development of visual impairment, which can be considered a late diagnosis. Surgical treatment of gonadotropinomy was carried out successfully and without complications, remission of the disease was achieved, visual function was restored, the patient successfully became pregnant.

23 February 2023 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ISIrina Stanoevich
Irina Stanoevich
VKV. V. Khvostovoy
V. V. Khvostovoy
ETE. I. Tishina
E. I. Tishina
VDV. I. Dyachkova
V. I. Dyachkova
DPDmitry V Petrochenko
Dmitry V Petrochenko
ISIrina Vasil’evna Stanoevich
Irina Vasil’evna Stanoevich
Purpose. To reflect the current understanding of the frequency, molecular mechanisms, and means of overcoming alopecia in cancer patients, taking into account the fundamental data of recent years on the physiology of the hair follicle and the pharmacological profile of the toxicity of anticancer drugs.Material and Methods. A literature search using Medline, Pubmed, etc. databases was carried out. More than 200 publications devoted to the study of alopecia were found, of which 42 were included in this review.Results. Chemotherapy-induced hair loss is a common adverse effect in cancer patients undergoing treatment. The frequency and molecular mechanism of the development of alopecia are related to the pharmacological features of the drug-based treatments, initial nutritional premorbid status, and predisposing polymorphisms of genes involved in drug conversion and excretion. Focal or diffuse alopecia may be the first sign of malignant growth within the paraneoplastic syndrome, primary or metastatic malignancies of the scalp, or be a manifestation of nutritional insufficiency. Baldness negatively affects the psycho-emotional state of patients, exacerbating depressive disorders, anxiety, reducing self-esteem and adherence to treatment. Thus, prevention or rapid overcoming of alopecia can significantly improve the quality of life of cancer patients. The use of scalp cooling or ‘cold caps’ is proven to be an effective way of combating chemotherapy-induced hair loss.Conclusion. Further studies are needed to prevent and treat alopecia in cancer patients.

30 December 2018 in Obesity and metabolism
Verified
Journal Article
Open access
PDF file
SVSvetlana Yu. Vorotnikova
Svetlana Yu. Vorotnikova
LDLarisa K Dzeranova
Larisa K Dzeranova
ISIrina Stanoevich
Irina Stanoevich
EPEKATERINA PIGAROVA
EKATERINA PIGAROVA
EAElena N. Andreeva
Elena N. Andreeva
VMValery P. Masenko
Valery P. Masenko
Background: The frequency of menstrual disorders in patients with acromegaly is 4084% and are caused by three main reasons the development of normal or hypogonadotropic hypogonadism due to hyperprolactinemia or a mass effect of the tumor and direct effects of GH and IGF-1 on the reproductive system. Nevertheless the exact mechanisms of reproductive dysfunction are not clear now. Hypothalamic structures play significant role in the regulation of hypothalamic-pituitary-ovary axis, so its important to study key neuropeptides and evaluate their effects to the pathogenesis of ovarian dysfunction during excessive secretion of growth hormone. Aim: The aim of the work is to study the hormonal regulation of menstrual function in patients of reproductive age with acromegaly in the active stage of the disease. Material and methods: The study included patients with a confirmed diagnosis of acromegaly and healthy women, comparable in age and BMI. Blood serum samples were taken in the morning (89 hours) on an empty stomach for 35 days of the menstrual cycle or on any day with amenorrhea and frozen at -70C. The hormonal study was carried out by an enzyme immunoassay, in the case of a kisspeptin, with the preliminary extraction of serum samples. Results: The study included 31 patients with acromegaly and 15 healthy women. Between groups there was a statistically significant decrease in levels of LH (p = 0.001), FSH (p = 0.09), inhibin B (p = 0.003), and kisspeptin (p = 0.00005). The frequency of hyperprolactinemia in the cohort of patients was 51.6%. During the correlation analysis, a negative dependence of kisspeptin on the levels of GH and IGF-1 was detected (r = -0.54, p = 0.002 and r = -0.63, p = 0.0002). Conclusions: The severity of the central depression of regulation of menstrual function in patients with acromegaly may be due to the degree of disease activity.

7 July 2017 in Endocrine Surgery
Verified
Journal Article
Open access
PDF file
ENElena Y. Nadezhdina
Elena Y. Nadezhdina
ZBZhanna Belaya
Zhanna Belaya
LRLudmila Y. Rozhinskaya
Ludmila Y. Rozhinskaya
VAVilen N. Azyzjan
Vilen N. Azyzjan
OIOksana V. Ivashenko
Oksana V. Ivashenko
AGAndrey Y. Grigoriev
Andrey Y. Grigoriev
Цель работы. Изучение динамического изменения интра- и ранних послеоперационных гормональных показателей (адренокортикотропного гормона (АКТГ) и кортизола) в качестве предикторов ремиссии гиперкортицизма. Материал и методы. Проведен сравнительный анализ результатов эндоскопической аденомэктомии у 50 пациентов с болезнью Иценко–Кушинга. Пациенты были разделены на три группы в зависимости от исхода операции. Первая группа – пациенты с вторичной надпочечниковой недостаточностью, подтвержденной клинической картиной и уровнем кортизола меньше 50 нмоль/л; вторая группа – с нормализацией уровней АКТГ и кортизола; третья – с персистенцией болезни Иценко–Кушинга. Оценена динамика снижения уровней АКТГ и кортизола во время операции и в раннем послеоперационном периоде. Группу составили 38 женщин и 12 мужчин в возрасте от 15 до 66 лет. Заборы крови для оценки уровней АКТГ и кортизола производились из периферической вены: первый – на этапе разреза твердой мозговой оболочки, второй – сразу после удаления опухоли и заключительный – через 20 мин после удаления аденомы. Затем исследование вышеуказанных гормонов проводилось всем пациентам через сутки после операции. Уровни АКТГ и кортизола определялись путем иммунохемилюминесцентного анализа на автоматизированной системе Сobas 6000 (Roche, Франция). Референсные интервалы АКТГ – 0–30 нг/мл, кортизола – 123–626 нмоль/л. Результаты. Не получено четкой зависимости между изменениями уровня исследуемых гормонов в интра- и раннем послеоперационном периоде (20 мин после удаления опухоли) и вероятностью наступления ремиссии заболевания (p > 0,0125). Результаты гормонального исследования через сутки коррелировали с частотой послеоперационной ремиссии (p < 0,0125). В послеоперационном периоде из 50 пациентов у 41 (82%) развилась надпочечниковая недостаточность, у 5 (10%) пациентов показатели нормализовались и у 4 (8%) пациентов наблюдалась персистенция гиперкортицизма. Заключение. Интраоперационное определение уровней АКТГ и кортизола не является целесообразным для оценки радикальности удаления опухоли.

20 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ISIrina Vasil’evna Stanoevich
Irina Vasil’evna Stanoevich
DPDmitry V Petrochenko
Dmitry V Petrochenko
ISIrina Stanoevich
Irina Stanoevich
EPEkaterina Pismennaya
Ekaterina Pismennaya
Background. The aim of the study was to develop a predictive model of anticancer drug therapy toxicity in patients with gastric cancer. Methods. The retrospective study included 100 patients with stage II-IV gastric cancer who underwent 4 chemotherapy cycles. Initial significant toxicity factors included age, gender, height, body mass, body mass index, disease stage, skeletal muscle index (SMI), as well as plasma levels of trace elements (copper, zinc, selenium, manganese) and thyroid-stimulating hormone, cancer histology type and treatment regimen. The CTCAE v5.0 scale was employed to assess the severity of adverse events. Statistical analysis and building of mathematical neural network models were carried out in SPSS Statistics (v19.0). Results. Lower SMI values were associated with higher rates of toxicity-related complications of anticancer drug therapy (р< 0.05): leukopenia, hypoproteinemia, nausea, vomiting, cardiovascular events. Anemia, thrombocytopenia, hepatic cytolysis syndrome, nausea, diarrhea, constipation and stomatitis showed a weaker correlation with SMI. An increase in TSH was associated with higher rates of thrombocytopenia, nausea and vomiting. A decrease in Cu/Zn in plasma correlated with the severity of leukopenia and diarrhea, whereas Se/Mn showed an inverse correlation with the severity of anemia. Conclusion. Sarcopenia, abnormal thyroid status and imbalances in copper, zinc, selenium and manganese in blood plasma of patients with gastric cancer may be used as predictors of increased toxicity of anticancer drug therapy.

15 November 2024 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
ISIrina Stanoevich
Irina Stanoevich
VKV. V. Khvostovoy
V. V. Khvostovoy
DPDmitry V Petrochenko
Dmitry V Petrochenko
ASA. Yu. Salamatina
A. Yu. Salamatina
VIVitaliy Ioutsi
Vitaliy Ioutsi
IEI. V. Ermilov
I. V. Ermilov
The purpose of the study was to carry out a systematic analysis of the data available in the modern literature on the essentiality of selenium in biological systems and the importance of selenoproteins in oncogenesis.Material and Methods. The publications were analyzed using Scopus (415), PubMed (521), Web of Science (139), eLibrary.ru (240) databases. To obtain full-text documents, the electronic resources PubMed Central (PMC), Science Direct, Research Gate, eLibrary.ru were used.Results. The need to use selenium compounds for the prevention and treatment of malignant neoplasms is controversial, and some selenoproteins have demonstrated a permissive role in oncogenesis, thus requiring further in-depth study in neoplasms of various histogenesis.Conclusion. It is necessary to continue comprehensive molecular studies of bioorganic selenium compounds at the morphological, ultrastructural and biochemical levels in tumors of various localizations, depending on the genetic characteristics of the studied population and the geochemical characteristics of the region.